The evolutionary safety of mutagenic drugs should be assessed before drug approval

Gabriela Lobinska; Vyacheslav Tretyachenko; Orna Dahan; Martin A. Nowak; Yitzhak Pilpel

doi:10.1371/journal.pbio.3002570

The evolutionary safety of mutagenic drugs should be assessed before drug approval

Gabriela Lobinska, Vyacheslav Tretyachenko, Orna Dahan, Martin A. Nowak^*, Yitzhak Pilpel^*

^*Corresponding author for this work

Department of Molecular Genetics

Research output: Contribution to journal › Article › peer-review

Abstract

Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.

Original language	English
Article number	e3002570
Journal	PLoS Biology
Volume	22
Issue number	3
DOIs	https://doi.org/10.1371/journal.pbio.3002570
Publication status	Published - 15 Mar 2024

All Science Journal Classification (ASJC) codes

General Neuroscience
General Biochemistry,Genetics and Molecular Biology
General Immunology and Microbiology
General Agricultural and Biological Sciences

Access to Document

10.1371/journal.pbio.3002570Licence: CC BY

Cite this

@article{e3f9277d0d974a10976a51d95764d0ff,

title = "The evolutionary safety of mutagenic drugs should be assessed before drug approval",

abstract = "Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.",

author = "Gabriela Lobinska and Vyacheslav Tretyachenko and Orna Dahan and Nowak, {Martin A.} and Yitzhak Pilpel",

year = "2024",

month = mar,

day = "15",

doi = "10.1371/journal.pbio.3002570",

language = "English",

volume = "22",

journal = "PLoS Biology",

issn = "1544-9173",

publisher = "Public Library of Science",

number = "3",

}

TY - JOUR

T1 - The evolutionary safety of mutagenic drugs should be assessed before drug approval

AU - Lobinska, Gabriela

AU - Tretyachenko, Vyacheslav

AU - Dahan, Orna

AU - Nowak, Martin A.

AU - Pilpel, Yitzhak

PY - 2024/3/15

Y1 - 2024/3/15

N2 - Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.

AB - Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.

UR - http://www.scopus.com/inward/record.url?scp=85188011622&partnerID=8YFLogxK

U2 - 10.1371/journal.pbio.3002570

DO - 10.1371/journal.pbio.3002570

M3 - Article

C2 - 38489394

AN - SCOPUS:85188011622

SN - 1544-9173

VL - 22

JO - PLoS Biology

JF - PLoS Biology

IS - 3

M1 - e3002570

ER -

The evolutionary safety of mutagenic drugs should be assessed before drug approval

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this